Edible Cannabis Products: It Is Time for FDA Oversight

被引：19

作者：

Benjamin, David M. ^{[1
]}

Fossler, Michael J. ^{[1
]}

机构：

[1] Amer Coll Clin Pharmacol, Publ Policy Comm, Ashburn, VA USA

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2016年 / 56卷 / 09期

关键词：

DELTA-9-TETRAHYDROCANNABINOL; MARIJUANA;

D O I：

10.1002/jcph.778

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：1045 / 1047

页数：3

共 8 条

[1]

[Anonymous], 2013, MAR DRON CAPS

[2]

Benjamin DM, 2014, 2 INT C NEUPS 2014 N

[3]

Benjamin DM, 2014, FORENSIC DRUG ABUSE, p[26, 53]

[4] Death Following Ingestion of an Edible Marijuana Product - Colorado, March 2014 [J].

Hancock-Allen, Jessica B. ;

Barker, Lisa ;

VanDyke, Michael ;

Holmes, Dawn B. .

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2015, 64 (28) :771-772

[5] BLOOD CANNABINOIDS .1. ABSORPTION OF THC AND FORMATION OF 11-OH-THC AND THCCOOH DURING AND AFTER SMOKING MARIJUANA [J].

HUESTIS, MA ;

HENNINGFIELD, JE ;

CONE, EJ .

JOURNAL OF ANALYTICAL TOXICOLOGY, 1992, 16 (05) :276-282

[6]

Hughes T., 2014, US TODAY WEEKEN 0509, p1A

[7] COMPARATIVE PHARMACOLOGY OF DELTA-9-TETRAHYDROCANNABINOL AND ITS METABOLITE, 11-OH-DELTA-9-TETRAHYDROCANNABINOL [J].

LEMBERGER, L ;

MARTZ, R ;

RODDA, B ;

FORNEY, R ;

ROWE, H .

JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (10) :2411-2417

[8] Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9 [J].

Sachse-Seeboth, C. ;

Pfeil, J. ;

Sehrt, D. ;

Meineke, I. ;

Tzvetkov, M. ;

Bruns, E. ;

Poser, W. ;

Vormfelde, S. V. ;

Brockmoeller, J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (03) :273-276

← 1 →